INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD
Clinical trial NCT05163717 · TERMINATED
Trial details
- NCT number
- NCT05163717
- Sponsor
- Impel Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-23
- Primary completion
- 2023-03-31
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.